ライフサイエンスコーパス: coccidioidomycosis

1 ngitis (CM) is a devastating complication of coccidioidomycosis.

2 be incorporated into a human vaccine against coccidioidomycosis.

3 United States and is the causative agent of coccidioidomycosis.

4 y be useful in the treatment of disseminated coccidioidomycosis.

5 mitis, was investigated in a murine model of coccidioidomycosis.

6 the parental isolate in our murine model of coccidioidomycosis.

7 dies support rAg2/PRA vaccination to prevent coccidioidomycosis.

8 duced the resistance of B6 mice to pulmonary coccidioidomycosis.

9 be essential components of a vaccine against coccidioidomycosis.

10 mmitis urease as a candidate vaccine against coccidioidomycosis.

11 e effective therapy for progressive forms of coccidioidomycosis.

12 involved in MyD88-dependent Th17 immunity to coccidioidomycosis.

13 rational target for therapy of disseminated coccidioidomycosis.

14 t sufficient to make C57BL mice resistant to coccidioidomycosis.

15 munoprotective capacity in a murine model of coccidioidomycosis.

16 nd is a valuable aid in the serodiagnosis of coccidioidomycosis.

17 rst-in-class orphan product for treatment of coccidioidomycosis.

18 antigen 2 (Ag2) gene vaccine in experimental coccidioidomycosis.

19 therapy could be used as adjunct therapy for coccidioidomycosis.

20 phic fungal pathogen that causes the disease coccidioidomycosis.

21 PRA as a candidate vaccine for prevention of coccidioidomycosis.

22 s a devastating complication of disseminated coccidioidomycosis.

23 ased the risk for being diagnosed with acute coccidioidomycosis.

24 examining the role of anti-Ag2 antibodies in coccidioidomycosis.

25 in prevention and early recognition of acute coccidioidomycosis.

26 a valuable diagnostic and prognostic aid in coccidioidomycosis.

27 offer improved accuracy for the diagnosis of coccidioidomycosis.

28 ses suggests potential benefit in refractory coccidioidomycosis.

29 e role of V/C salvage therapy for refractory coccidioidomycosis.

30 t report of an epitope-based vaccine against coccidioidomycosis.

31 active or occult infection can also transmit coccidioidomycosis.

32 ccine, are fully protected against pulmonary coccidioidomycosis.

33 immunotherapeutic protocols for treatment of coccidioidomycosis.

34 h prophylaxis did not experience reactivated coccidioidomycosis.

35 ive and IgG-negative EIA result did not have coccidioidomycosis.

36 EIA are thought to have a diagnosis of acute coccidioidomycosis.

37 ts for IgM among persons suspected of having coccidioidomycosis.

38 e in vitro testing of vaccine candidates for coccidioidomycosis.

39 rotects both BALB/c and C57BL/6 mice against coccidioidomycosis.

40 ilitate improved treatment and prevention of coccidioidomycosis.

41 tment course was complicated by disseminated coccidioidomycosis.

42 ation of a cellular immune response in human coccidioidomycosis.

43 inclusion in a vaccine candidate to prevent coccidioidomycosis.

44 s as well as from patients with disseminated coccidioidomycosis.

45 olved, and 83% in disseminated and meningeal coccidioidomycosis.

46 ine against C. posadasii in a mouse model of coccidioidomycosis.

47 posadasii) are the causative agents of human coccidioidomycosis.

48 gely derived from murine models of pulmonary coccidioidomycosis.

49 n the donor lungs, leading to posttransplant coccidioidomycosis.

50 -month study of patients being evaluated for coccidioidomycosis, 1 or more serum samples were obtaine

51 elve received a diagnosis of acute pulmonary coccidioidomycosis, 17 received other diagnoses, and 17

52 ged > or =60 years with laboratory-confirmed coccidioidomycosis; 2 control groups were selected, the

53 f 47 transplant recipients with a history of coccidioidomycosis, 44 had quiescent infection at transp

54 t assays with sera from patients with active coccidioidomycosis, a hyperimmune goat anti-Ag2 serum, a

55 P) antibody present in sera of patients with coccidioidomycosis, a reaction which has been used for s

56 phylaxis effectively suppressed recrudescent coccidioidomycosis after solid organ transplantation for

57 stantially decreased the risk of reactivated coccidioidomycosis after transplantation in these patien

58 nfection, azoles suppressed any recrudescent coccidioidomycosis after transplantation.

59 action, PBMC from subjects with disseminated coccidioidomycosis also expressed less mRNA for IFN-gamm

60 Coccidioidomycosis (also known as San Joaquin Valley fev

61 t of each patient's individual circumstances.Coccidioidomycosis, also known as San Joaquin Valley fev

62 tistically superior efficacy in nonmeningeal coccidioidomycosis, although there is a trend toward sli

63 An outbreak of coccidioidomycosis among 22 Navy SEALs occurred during t

64 Because of the increase in incidence of coccidioidomycosis among the elderly in Arizona between

65 Coccidioidomycosis, an endemic fungal infection in the d

66 Coccidioidomycosis, an endemic fungal infection seen thr

67 Coccidioidomycosis, an infection endemic to the southwes

68 Serum samples from 103 cases of coccidioidomycosis and 373 controls were tested for IgG

69 owed reactivity with sera from patients with coccidioidomycosis and elicited delayed-type footpad hyp

70 Ag nonresponsive patients with disseminated coccidioidomycosis and healthy nonimmune individuals.

71 een used for the diagnosis of other forms of coccidioidomycosis and meningitis caused by other mycose

72 th CD4+ and CD8+ T cells can protect against coccidioidomycosis and that TNF- alpha is a necessary co

73 romising vaccine candidate for prevention of coccidioidomycosis and warrants further investigation.

74 ibody in 21 (95%) of 22 patients with active coccidioidomycosis and was without reactivity with sera

75 in 5 practices within the areas endemic for coccidioidomycosis (Arizona, California, and Nevada).

76 after antigen stimulation from subjects with coccidioidomycosis as compared to those with another dia

77 be at higher risk for developing symptomatic coccidioidomycosis as compared with those not receiving

78 At least 11 of these 49 patients had coccidioidomycosis as determined by culture or subsequen

79 onse in PBMC from patients with disseminated coccidioidomycosis as well as healthy nonimmune individu

80 Of the three with active coccidioidomycosis at transplantation, two were taking a

81 ofungin (V/C) salvage therapy for refractory coccidioidomycosis at two children's hospitals between J

82 e respiratory distress syndrome secondary to coccidioidomycosis because of the fear of enhancing fung

83 large majority of patients with a history of coccidioidomycosis before transplantation.

84 ar Lv is responsible for early resistance to coccidioidomycosis but not for modulating the IL-10 and

85 cting CF antibody in sera from patients with coccidioidomycosis but was not specific to C. immitis, a

86 ination may be a risk factor for reactivated coccidioidomycosis, but this finding was not statistical

87 dioides sp., the etiological agents of human coccidioidomycosis, but with a travel history including

88 We investigated secondary immunity against coccidioidomycosis by using gene expression microarrays.

89 We conclude that coccidioidomycosis can be caused by two distinct noninte

90 Reports of coccidioidomycosis cases in Arizona have increased subst

91 and March 15, 1994, 203 outbreak-associated coccidioidomycosis cases, including 3 fatalities, were i

92 Coccidioidomycosis causes a substantial disease burden i

93 d in samples from those with acute pulmonary coccidioidomycosis, compared with the other 2 groups (fo

94 Coccidioidomycosis continues to be a threat to military

95 blood obtained from patients with pulmonary coccidioidomycosis demonstrated specific cellular immune

96 The outcome of coccidioidomycosis depends to a large extent on the effe

97 center to identify factors for recrudescent coccidioidomycosis (despite antifungal prophylaxis) afte

98 Only 8% of participants were aware of coccidioidomycosis, despite the majority having visited

99 BAL fluid from patients living in a coccidioidomycosis-endemic region of Arizona who were un

100 A major epidemic of coccidioidomycosis (etiologic agent, Coccidioides immiti

101 Children's Hospital Central California with coccidioidomycosis from 1 January 2010 to 1 September 20

102 Elderly persons with coccidioidomycosis had spent significantly less time in

103 Development of a human vaccine against coccidioidomycosis has focused on recombinant T-cell-rea

104 Coccidioides posadasii in a murine model of coccidioidomycosis has led to the discovery of potential

105 The utility of this assay in coccidioidomycosis has not been previously studied.

106 data suggest that patients with disseminated coccidioidomycosis have a diminished T helper lymphocyte

107 Clinical and animal studies of coccidioidomycosis have demonstrated that activated CD4(

108 veolar lavage (BAL) fluid in acute pulmonary coccidioidomycosis have not been defined.

109 sorbent assays using sera from patients with coccidioidomycosis, histoplasmosis, or blastomycosis.

110 Patients with coccidioidomycosis identified only by newer tests had fe

111 A North Carolinian developed fatal coccidioidomycosis immediately after bilateral lung tran

112 as defined as laboratory-confirmed, incident coccidioidomycosis in a person infected with HIV for > o

113 Coccidioidomycosis in Arizona has increased.

114 (MR) and Dectin-2 in resistance to pulmonary coccidioidomycosis in C57BL/6 (B6) mice and in the inter

115 y was conducted to evaluate risk factors for coccidioidomycosis in HIV-infected persons.

116 uary 1995 through 31 June 1997, 153 cases of coccidioidomycosis in human immunodeficiency virus (HIV)

117 a promising vaccine candidate for preventing coccidioidomycosis in humans or other animals.

118 near Tnfr1 are associated with resistance to coccidioidomycosis in mice.

119 ns need to be aware of their higher risk for coccidioidomycosis in order to improve their chances of

120 Herein, we review available data on coccidioidomycosis in solid organ transplant recipients

121 We report an unusual case of coccidioidomycosis in the arm of a veterinary assistant

122 enic fungus that causes endemic and epidemic coccidioidomycosis in the deserts of North, Central, and

123 cal experience treating medically refractory coccidioidomycosis in the pediatric population with conc

124 We describe a case of coccidioidomycosis in which several unusual morphologic

125 rrent epidemics of San Joaquin Valley fever (coccidioidomycosis) in desert regions of the southwester

126 ntal studies indicate that prior symptomatic coccidioidomycosis induces immunity against subsequent i

127 atory distress syndrome owing to a fulminant coccidioidomycosis infection that responded to a short c

128 3%) additional patients developed "possible" coccidioidomycosis infections.

129 Coccidioidomycosis is a common cause of community-acquir

130 Coccidioidomycosis is a common fungal infection acquired

131 Coccidioidomycosis is a fungal infection endemic in the

132 Coccidioidomycosis is a fungal infection that is endemic

133 Coccidioidomycosis is a human respiratory disease that i

134 Coccidioidomycosis is a potentially life-threatening res

135 Coccidioidomycosis is a respiratory disease of humans ca

136 Coccidioidomycosis is a spectrum of diseases caused by t

137 Coccidioidomycosis is an airborne infection caused by th

138 Coccidioidomycosis is an endemic fungal infection of the

139 Coccidioidomycosis is an increasingly important health p

140 Extrathoracic dissemination of coccidioidomycosis is associated with a lack of cellular

141 identification of candidate vaccines against coccidioidomycosis is both efficient and productive.

142 m vaccination, once an effective vaccine for coccidioidomycosis is developed.

143 This study suggests that the risk of serious coccidioidomycosis is low among military personnel durin

144 will be unfamiliar with how skin testing for coccidioidomycosis might be useful in patient management

145 tional recommendations address management of coccidioidomycosis occurring for special at-risk populat

146 Coccidioides posadasii causes coccidioidomycosis, or Valley fever, in the endemic regi

147 This is the first report of a coccidioidomycosis outbreak following an earthquake.

148 nd timing of cases strongly suggest that the coccidioidomycosis outbreak in Ventura County was caused

149 ed to 1.7 in DTH-negative donors with active coccidioidomycosis (P = 0.03).

150 ing the purified rCts1(Ur), 74 out of the 77 coccidioidomycosis patients examined (96.1%) were positi

151 -linked immunosorbent assays of sera from 28 coccidioidomycosis patients.

152 eed for a rapid and safe means of diagnosing coccidioidomycosis prompted us to develop a real-time PC

153 asis to be associated with increased risk of coccidioidomycosis; protease inhibitor therapy was assoc

154 Coccidioidomycosis ranges from a mild to a severe infect

155 eiving other therapies developed symptomatic coccidioidomycosis (relative risk 5.23, 95% confidence i

156 The in situ immunologic response in human coccidioidomycosis remains undefined.

157 of 0.16 +/- 0.04, patients with disseminated coccidioidomycosis showed a mean response of 0.69 +/- 0.

158 of lists of persons with negative serologic coccidioidomycosis tests (laboratory-negative controls,

159 ly higher in DTH-positive donors with active coccidioidomycosis than in healthy, nonimmune controls (

160 sed by all biopsied lesions of patients with coccidioidomycosis that we examined, whether localized t

161 f the 22 men had serologic evidence of acute coccidioidomycosis, the highest attack rate ever reporte

162 ced protective immunity against experimental coccidioidomycosis through the induction of Th1-associat

163 99 and June 2009, 100 patients with previous coccidioidomycosis underwent solid organ transplantation

164 fungus responsible for a recent epidemic of coccidioidomycosis (Valley fever) in California.

165 rmation of the importance of B cells against coccidioidomycosis was achieved by demonstrating that va

166 the relative risk of developing symptomatic coccidioidomycosis was calculated in patients with infla

167 Given the patients' lack of recent travel, coccidioidomycosis was not suspected, leading to delays

168 Serology for coccidioidomycosis was positive in six patients.

169 Coccidioidomycosis was recognized or considered in only

170 d for 72 h from 8 subjects with disseminated coccidioidomycosis was significantly less than that from

171 going transplantation in an area endemic for coccidioidomycosis, we recommend routine evaluation for

172 are required for vaccine-induced immunity to coccidioidomycosis, we used a temperature-sensitive muta

173 Thirteen cases of documented coccidioidomycosis were associated with TNF alpha antago

174 idence suggest that 3 individuals with acute coccidioidomycosis were exposed in Washington State, sig

175 Cases of coccidioidomycosis were identified and reviewed from amo

176 Nine children with refractory coccidioidomycosis were treated with V/C salvage therapy

177 ne responses from patients with disseminated coccidioidomycosis who are nonresponsive to coccidioidal

178 a retrospective review of all patients with coccidioidomycosis who underwent solid organ transplanta

179 he medical records of 47 patients with prior coccidioidomycosis who underwent solid organ transplanta

180 ent of the ability to control the problem of coccidioidomycosis will require research into the molecu

181 We investigated a case of disseminated coccidioidomycosis with hypercalcemia.